Cargando…
Furosemide for postpartum blood pressure control in patients with hypertensive disorders
OBJECTIVE: diuretics have the potential to reduce intravascular volume, decrease blood pressure The aim of our study is to evaluate the effectiveness of furosemide in postpartum patients with pre-eclampsia and chronic hypertension with superimposed pre-eclampsia. METHODS: This is a retrospective coh...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192387/ https://www.ncbi.nlm.nih.gov/pubmed/37214156 http://dx.doi.org/10.1016/j.eurox.2023.100195 |
_version_ | 1785043617740488704 |
---|---|
author | Pagan, Megan Ounprpaseuth, Songthip T. Ghahremani, Taylor Doiron, Tucker Magann, Everett F. |
author_facet | Pagan, Megan Ounprpaseuth, Songthip T. Ghahremani, Taylor Doiron, Tucker Magann, Everett F. |
author_sort | Pagan, Megan |
collection | PubMed |
description | OBJECTIVE: diuretics have the potential to reduce intravascular volume, decrease blood pressure The aim of our study is to evaluate the effectiveness of furosemide in postpartum patients with pre-eclampsia and chronic hypertension with superimposed pre-eclampsia. METHODS: This is a retrospective cohort study. Data was extracted from the record of patients who delivered between 2017 and 2020 and had chronic hypertension or, chronic hypertension with superimposed pre-eclampsia, gestational hypertension, or pre-eclampsia. Patients who received intravenous furosemide in the postpartum period were compared to those who did not. The groups were also analyzed for fetal growth restriction, and pregnancy outcomes comparing those who did receive furosemide and those who did not. RESULTS: The furosemide group had a statistically significant longer postpartum length of stay (p < 0.0001), required more antihypertensive medications (p < 0.0001), medication increases (p < 0.0001), and emergent blood pressure treatment (p < 0.0001), than the group who did not. There was no difference between groups in hospital readmission, or fetal growth restriction. CONCLUSION: The postpartum length of stay and rates of readmission were not decreased in the group treated with intravenous furosemide. Future prospective studies that control for pregnancy comorbidities and severity of preeclampsia are needed to determine furosemide’s effect on the volume status of the postpartum pre-eclamptic patient and determine its role in the treatment of these women. |
format | Online Article Text |
id | pubmed-10192387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101923872023-05-19 Furosemide for postpartum blood pressure control in patients with hypertensive disorders Pagan, Megan Ounprpaseuth, Songthip T. Ghahremani, Taylor Doiron, Tucker Magann, Everett F. Eur J Obstet Gynecol Reprod Biol X Obstetrics and Maternal Fetal Medicine OBJECTIVE: diuretics have the potential to reduce intravascular volume, decrease blood pressure The aim of our study is to evaluate the effectiveness of furosemide in postpartum patients with pre-eclampsia and chronic hypertension with superimposed pre-eclampsia. METHODS: This is a retrospective cohort study. Data was extracted from the record of patients who delivered between 2017 and 2020 and had chronic hypertension or, chronic hypertension with superimposed pre-eclampsia, gestational hypertension, or pre-eclampsia. Patients who received intravenous furosemide in the postpartum period were compared to those who did not. The groups were also analyzed for fetal growth restriction, and pregnancy outcomes comparing those who did receive furosemide and those who did not. RESULTS: The furosemide group had a statistically significant longer postpartum length of stay (p < 0.0001), required more antihypertensive medications (p < 0.0001), medication increases (p < 0.0001), and emergent blood pressure treatment (p < 0.0001), than the group who did not. There was no difference between groups in hospital readmission, or fetal growth restriction. CONCLUSION: The postpartum length of stay and rates of readmission were not decreased in the group treated with intravenous furosemide. Future prospective studies that control for pregnancy comorbidities and severity of preeclampsia are needed to determine furosemide’s effect on the volume status of the postpartum pre-eclamptic patient and determine its role in the treatment of these women. Elsevier 2023-05-03 /pmc/articles/PMC10192387/ /pubmed/37214156 http://dx.doi.org/10.1016/j.eurox.2023.100195 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Obstetrics and Maternal Fetal Medicine Pagan, Megan Ounprpaseuth, Songthip T. Ghahremani, Taylor Doiron, Tucker Magann, Everett F. Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title | Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title_full | Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title_fullStr | Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title_full_unstemmed | Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title_short | Furosemide for postpartum blood pressure control in patients with hypertensive disorders |
title_sort | furosemide for postpartum blood pressure control in patients with hypertensive disorders |
topic | Obstetrics and Maternal Fetal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192387/ https://www.ncbi.nlm.nih.gov/pubmed/37214156 http://dx.doi.org/10.1016/j.eurox.2023.100195 |
work_keys_str_mv | AT paganmegan furosemideforpostpartumbloodpressurecontrolinpatientswithhypertensivedisorders AT ounprpaseuthsongthipt furosemideforpostpartumbloodpressurecontrolinpatientswithhypertensivedisorders AT ghahremanitaylor furosemideforpostpartumbloodpressurecontrolinpatientswithhypertensivedisorders AT doirontucker furosemideforpostpartumbloodpressurecontrolinpatientswithhypertensivedisorders AT maganneverettf furosemideforpostpartumbloodpressurecontrolinpatientswithhypertensivedisorders |